Cidofovir 375 mg Injection

Get a Price/Quote

MOQ : 10 Boxes

Cidofovir 375 mg Injection Specification

Dosage Form
Injection

Usage
For intravenous use in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients

CAS No
113852-37-2

Salt Composition
Cidofovir

Grade
Pharmaceutical Grade

Indication
Cytomegalovirus (CMV) retinitis

Origin of Medicine
India

Assay
Not less than 98.5% and not more than 101.5%

Molecular Formula
C8H14N3O6P

Appearance
Clear, colorless solution

Expiration Date
24 months from the date of manufacture

Storage
Store at 2C to 8C, protect from light

Medicine Type
Injection

Pacakaging (Quantity Per Box)
1 vial per box

Dosage
375 mg/5 ml

Container Type
Glass vial

Registration Status
WHO-GMP Certified

Strength
375 mg/vial

Contraindications
Hypersensitivity to cidofovir or any component

Instructions for Use
Should be administered by a healthcare professional

Caution
Renal function monitoring required before and during therapy

Shelf Life
2 years under recommended storage

Route of Administration
Intravenous

Preservative
No preservative

Formulation
Sterile solution

Cidofovir 375 mg Injection Trade Information

Minimum Order Quantity
10 Boxes

Payment Terms
Cash in Advance (CID)

Supply Ability
500 Boxes Per Month

Delivery Time
7 Days

Main Domestic Market
All India

About Cidofovir 375 mg Injection

Discover a Special Rate on our hot-selling Cidofovir 375 mg Injection-an esteemed solution in combating cytomegalovirus (CMV) retinitis in AIDS patients. Renowned for its prime efficacy, this sterile intravenous pharmaceutical grade formulation comes in a high-quality glass vial with a clear, colorless appearance. Each vial contains 375 mg/5 ml cidofovir, with assay values between 98.5% and 101.5%, and is entirely preservative-free. Registered under WHO-GMP certification and sourced from India's leading suppliers, this deal ensures a lofty standard of safety, reliability, and international compliance. Shelf life extends up to 2 years under optimal conditions.

Therapeutic Usage and Applications

Cidofovir 375 mg Injection is administered intravenously, serving as a potent antiviral agent in the management of cytomegalovirus (CMV) retinitis among AIDS patients. It is used exclusively under professional supervision for systemic therapy, ensuring targeted application within the body's vascular surfaces. Designed for single-use per vial, its medical-grade formulation ensures optimal bioavailability and controlled release, making it indispensable in specialized hospital and clinical settings.

Certifications, Sampling, and Payment Modalities

Backed by WHO-GMP certification, Cidofovir 375 mg Injection meets global pharmaceutical standards, offering assurance of quality and compliance. Sample vials are available for preliminary evaluation prior to full-scale outlay. Flexible payment terms facilitate seamless transactions, ensuring delivery is prompt and all consignments are delivered to meet timelines. Exporters, suppliers, traders, and wholesalers can trust in streamlined logistics and reliable support from the initial inquiry to final delivery.

FAQ's of Cidofovir 375 mg Injection:

Q: How is Cidofovir 375 mg Injection administered?

A: Cidofovir 375 mg Injection is administered as an intravenous infusion by a qualified healthcare professional in a controlled medical environment.

Q: What are the main benefits of using this injection for CMV retinitis?

A: The main benefit is its targeted antiviral activity against cytomegalovirus, making it effective in managing CMV retinitis in patients with AIDS, thus helping to prevent vision loss.

Q: When should renal function be monitored during therapy?

A: Renal function should be closely monitored both before and during the course of Cidofovir therapy, as the injection may impact kidney function.

Q: Where is this product manufactured and by whom is it registered?

A: This product is manufactured in India and holds WHO-GMP certification, ensuring global pharmaceutical standards are met.

Q: What makes Cidofovir 375 mg Injection a hot-selling and prime choice?

A: Its lofty assay of not less than 98.5%, standardized sterile preparation, and absence of preservatives, combined with robust international certification, positions it as a preferred deal among healthcare providers.

Q: What precautions must be observed before using the injection?

A: Patients with known hypersensitivity to cidofovir or any component should not use this injection, and renal function must be thoroughly evaluated and monitored before initiation.

Tell us about your requirement